---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-064372"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-05T00:09:01.261122+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience appoints former Biogen CMO Maha Radhakrishnan to board

## Summary
- Dr. Radhakrishnan, age 54, appointed as Class I director effective March 8, 2024; term expires at 2025 Annual Meeting.
- Former Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024); earlier roles at Sanofi and Bioverativ.
- Board determined she is independent under NYSE and SEC rules; will serve on Nominating and Corporate Governance Committee.
- Receives initial option for 30,574 shares vesting over 3 years, annual option for 15,287 shares, and cash retainers ($40k board + $5k NCGC).
- Company entered standard indemnification agreement with Dr. Radhakrishnan.

## SEC filing metadata
- accession: 0001193125-24-064372
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000119312524064372/0001193125-24-064372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000119312524064372/d764642d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-064372
- JSON: https://secwatch.observer/filing/0001193125-24-064372.json
- Plain text: https://secwatch.observer/filing/0001193125-24-064372.txt

## Key facts
- Executive change
  Maha Radhakrishnan was appointed as Director at Alto Neuroscience, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000119312524064372/0001193125-24-064372-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.